Ignite Creation Date:
2025-12-24 @ 3:36 PM
Ignite Modification Date:
2026-01-07 @ 3:45 PM
Study NCT ID:
NCT03552692
Status:
TERMINATED
Last Update Posted:
2023-12-12
First Post:
2018-05-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma
Sponsor:
Fondazione Italiana Linfomi - ETS
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-09-25
Start Date Type:
ACTUAL
Primary Completion Date:
2020-03-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-02-17
Completion Date Type:
ACTUAL
First Submit Date:
2018-05-10
First Submit QC Date:
None
Study First Post Date:
2018-06-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-11
Last Update Post Date:
2023-12-12
Last Update Post Date Type:
ACTUAL